reports
ALK presented comprehensive data on two new paediatric AIT tablets and...
ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025 At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented extensive data on anaphylaxis and paediatric allergy. During the EAACI 2025 scientific programme, ALK sponsored two major symposia and participated at several oral sessions, presenting data on the latest innovation in anaphylaxis, children with respiratory allergy, and recent advanc...
ALK participates at Jefferies Global Healthcare Conference 2025 in New...
ALK participates at Jefferies Global Healthcare Conference 2025 in New York ALK (ALKB:DC / OMX: ALK B) today announced that the company is participating at the Jefferies Global Healthcare Conference 2025 in New York City taking place from 3 - 5 June 2025. Claus Steensen Sølje, Executive Vice President and CFO, this morning (EDT) participated in a fireside chat at the conference. A webcast replay of the fireside chat is available on ALK's investor site: or through this . ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. , mobile Media:...
ITULATEK® approved for treatment of children and adolescents in Canada
ITULATEK® approved for treatment of children and adolescents in Canada ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, hazel, and/or oak, in children, adolescents, and adults five to 65 years of age in Canada. Outside Europe, Can...
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Healthcare Research
- Morten Larsen
Three-month interim report (Q1) 2025 (unaudited) - English version onl...
Three-month interim report (Q1) 2025 (unaudited) - English version only Bemærk venligst, at rapporten udelukkende forefindes på engelsk. ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free cash flow almost tripled. Outlook remains unchanged. Performance highlights Comparative figures for Q1 2024 are shown in brackets. Growth rates are ...
Three-month interim report (Q1) 2025 (unaudited)
Three-month interim report (Q1) 2025 (unaudited) ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth in tablet sales. The operating profit margin of 31% partly reflected seasonality in ALK’s earnings. Free cash flow almost tripled. Outlook remains unchanged. Performance highlights Comparative figures for Q1 2024 are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated. Total revenue increased by 12% to ...
- ABGSC Healthcare Research
- Morten Larsen
ALK indgår co-promotion-aftale vedrørende neffy® i USA
ALK indgår co-promotion-aftale vedrørende neffy® i USA Co-promotion-aftale med ARS Pharma baseret på omkostningsdeling og performance-baseret indtægtsdeling.ALK fremskynder opbygningen af selskabets pædiatriske salgskanal på en balanceret måde. Aftalen påvirker ikke ALK's forventninger til omsætning og indtjening i 2025. ALK (ALKB.DC / OMX: ALK B) har i dag annonceret en fireårig aftale med amerikanske ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY) om markedsføring af neffy® (adrenalinnæsespray) til op mod 9.000 børnelæger i USA. Disse børnelæger står aktuelt for tæt på 10% af all...
ALK enters into neffy® co-promotion agreement in the USA
ALK enters into neffy® co-promotion agreement in the USA Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way. Agreement does not change ALK’s revenue and earnings outlook for 2025. ALK (ALKB.DC / OMX: ALK B) today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY) to co-promote the neffy® adrenaline (epinephrine) nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% o...
Invitation til præsentation af ALK’s regnskab for første kvartal 2025 ...
Invitation til præsentation af ALK’s regnskab for første kvartal 2025 tirsdag den 6. maj 2025 ALK (ALKB.DC / OMX: ALK B) offentliggør delårsrapport for de første tre måneder af 2025 (Q1) om morgenen tirsdag den 6. maj 2025. ALK afholder senere samme dag kl. 11.00 (CEST) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR-chef. Live audio-webcast Mødet audiocastes live på , hvor genafspilning a...
Invitation to the presentation of ALK’s first quarter 2025 results on ...
Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025 ALK (ALKB.DC / OMX: ALK B) will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025. Later on the same day, the company will host a presentation for investors and analysts at 11:00 a.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio web...
ITULAZAX®-tablet mod træpollenallergi godkendt til behandling af børn ...
ITULAZAX®-tablet mod træpollenallergi godkendt til behandling af børn i Europa ALK (ALKB.DC / OMX: ALK B) har i dag annonceret, at sundhedsmyndighederne i 17 EU-lande via en type II-variationsprocedure har godkendt selskabets europæiske registreringsansøgning for ITULAZAX® (sublingual allergi-immunterapi-tablet mod træpollenallergi) til behandling af børn og unge i alderen fem til 17 år. De første lanceringer forventes at finde sted over de kommende måneder forud for 2025/2026-initieringsssæsonen for nye patienter, som begynder behandling med pollenallergitabletter. ALK’s koncerndirektør ...
ITULAZAX® tree pollen tablet approved for treatment of children in Eur...
ITULAZAX® tree pollen tablet approved for treatment of children in Europe ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries via a type II variation procedure. First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on pollen allergy tablets. Executive Vice President of R&D, Hen...
Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til dir...
Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 14. marts 2024, og i tråd med selskabets sædvanlige praksis har bestyrelsen truffet beslutning om at tildele indtil i alt 250.000 aktiebaserede instrumenter i overensstemmelse med selskabets langsigtede incitamentsprogram (LTIP) for direktion og en kreds af ledende medarbejdere for 2025. Formålet med LTIP er at tilskynde og belønne langsigtet værdiskabe...
Grant of share-based long-term incentive instruments to members of the...
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees ALK (ALKB:DC / OMX: ALK B / AKBLF): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 14 March 2024 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 250,000 share-based instruments for the purpose of the company’s long-term incentive plan (LTIP) for the Board of Management and key employees for 2025. The objectives of the LTIP are to incentivise and reward long-term...
Generalforsamling i ALK-Abelló A/S afholdt den 13. marts 2025
Generalforsamling i ALK-Abelló A/S afholdt den 13. marts 2025 ALK (ALKB:DC / OMX: ALK B / AKBLF): ALK-Abelló A/S afholdt ordinær generalforsamling den 13. marts 2025. På generalforsamlingen skete følgende: Årsrapport 2024 blev godkendt, og der blev meddelt decharge for bestyrelse og direktion.Der blev truffet beslutning om ikke at udbetale ordinært udbytte i henhold til den godkendte årsrapport for 2024, og at resultatet blev disponeret i henhold til den godkendte årsrapport.Vederlagsrapporten for 2024 blev godkendt.Bestyrelsens vederlag for indeværende år blev godkendt. Anders Hedegaard...
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025 ALK (ALKB:DC / OMX: ALK B / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 13 March 2025. The Annual General Meeting transacted the following business: Approval of the annual report 2024 and discharge of the Board of Directors and Board of ManagementResolution not to declare ordinary dividend in accordance with the approved annual report for 2024 and to allocate the profits in accordance with the approved annual reportAdoption of the remuneration report for 2024Adoption of the remuneration to the Board of Directors ...
ACARIZAX® approved in Canada for treatment of young children
ACARIZAX® approved in Canada for treatment of young children ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s ACARIZAX® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX® is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65. Outside Europe, Canada is one of the most important markets for ALK’s respiratory tablet portfolio with sales growing continuously by double digits. The expanded ACARIZAX®...
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier ...
Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU-forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende medarbejderes transaktioner: Bestyrelsen har tidligere tildelt aktieoptioner og performance-aktier i ALK-Abelló A/S, jf. selskabsmeddelelse nr. 07/2022 af 24. marts 2022. Retten til aktieoptioner og performance-aktier kunne opnås i marts 2025, under forudsætning af, at ALK opnår de forud aftalte mål...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.